Low prevalence of glomerulonephritis in transplanted kidneys from deceased donors with active hepatitis C virus infection
The mean age was 40.3 versus 40.7 years for HCV-RNA<sup>+</sup> versus HCV-negative donors, respectively. Expert pathology reviews showed that glomerular disease and isolated immune complex deposition were rare in both groups. The primary outcome of glomerulosclerosis, interstitial fibrosis with tubular atrophy, and/or vascular disease was non-inferior (15% margin) for HCV-RNA<sup>+</sup> versus HCV-negative donor kidneys. Specifically, 61.2% versus 49% had under 5% glomerulosclerosis, 68% versus 58% had under 5% interstitial fibrosis with tubular atrophy, and 46% versus 25% had no vascular disease, for HCV-RNA<sup>+</sup> versus HCV-negative donor kidneys, respectively. The recipients of kidney transplants from HCV-RNA<sup>+</sup> donors and HCV-negative comparators both demonstrated good graft function and 12-month eGFR was not significantly different between groups (1.65 ml/min/1.73 m<sup>2</sup> higher eGFR for HCV-RNA<sup>+</sup> allograft recipients.) CONCLUSIONS: Our findings indicate that for HCV-RNA<sup>+</sup> donor kidneys, glomerular disease was rare and chronic disease pathology was not more common than among HCV-negative kidneys, which may reassure clinicians to consider these organs for their patients.
Authors
- Derek A. DuBay (ORCID: https://orcid.org/0000-0001-8053-9695)
- David Seth Goldberg (ORCID: https://orcid.org/0000-0002-1465-0691)
- Rita R. Alloway (ORCID: https://orcid.org/0000-0003-4835-9197)
- Christine M. Durand (ORCID: https://orcid.org/0000-0003-2605-9257)
- Douglas Earl Schaubel (ORCID: https://orcid.org/0000-0002-9792-4474)
- Anne M. Huml (ORCID: https://orcid.org/0000-0002-6224-0785)
- E. Steve Woodle (ORCID: https://orcid.org/0000-0003-4280-0842)
- Michael B. Stokes (ORCID: https://orcid.org/0000-0003-0958-7672)
- Vishnu S. Potluri (ORCID: https://orcid.org/0000-0002-3307-8926)
- Sumit Mohan (ORCID: https://orcid.org/0000-0002-5305-9685)
- Elizabeth C. Verna (ORCID: https://orcid.org/0000-0002-9658-3751)
- Meghan E. Sise (ORCID: https://orcid.org/0000-0002-4327-9713)
- Rachel C. Forbes (ORCID: https://orcid.org/0000-0001-6827-791X)
- Therese Bittermann (ORCID: https://orcid.org/0000-0002-8576-0193)
- Peter P. Reese (ORCID: https://orcid.org/0000-0003-1440-069X)
- David R. Shaffer (ORCID: https://orcid.org/0000-0002-3040-7499)
- Shikha Mehta (ORCID: https://orcid.org/0000-0001-6616-4866)
- Niraj M. Desai (ORCID: https://orcid.org/0000-0002-0457-3506)
- Nianfu Song
- Dominick Santoriello (ORCID: https://orcid.org/0000-0001-5854-4236)
- Beatrice P. Concepcion (ORCID: https://orcid.org/0000-0002-0576-6756)
- Javier Pagán (ORCID: https://orcid.org/0000-0002-9351-4048)
- John W. McGillicuddy (ORCID: https://orcid.org/0000-0003-1847-1954)
- M. Díez Blanco
- Raymond T. Chung
Institutions
- Prisma Health (US)
- Northwell Health (US)
- Cleveland Clinic (US)
- Johns Hopkins University (US)
- University of Miami (US)
- Medical University of South Carolina (US)
- University of Alabama (US)
- Johns Hopkins Medicine (US)
- North Shore University Hospital (US)
- University of Alabama at Birmingham (US)
- University of Chicago (US)
- Massachusetts General Hospital (US)
- Pediatric Nephrology of Alabama (US)
- University of Cincinnati (US)
- Columbia University (US)
- University of Pennsylvania (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Kidney International
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.kint.2025.07.026
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Miami
- Sylvester Comprehensive Cancer Center, University of Miami Health Systems
- National Institutes of Health
- National Cancer Institute